Skip to search formSkip to main contentSkip to account menu

ADR-529

Known as: ADR 529, ADR529 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Carbon nanotubes (CNTs) were discovered in 1991 and shown to have certain unique physicochemical properties, attracting… 
2001
Highly Cited
1996
Highly Cited
1996
Dexrazoxane [(DZR), ADR 529, ICRF-187] ameliorates doxorubicin (DOX)-induced cardiotoxicity in animals, and is recommended as a… 
Review
1995
Review
1995
Chemotherapy drugs have been reported to cause cardiac side effects including cardiomyopathy, ischemia, arrhythmias, and… 
Highly Cited
1994
Highly Cited
1994
Certain bis(2,6-dioxopiperazine) derivatives, which include ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl]propane; ADR-529) and… 
Highly Cited
1992
Highly Cited
1992
In this study doxorubicin, epirubicin, and mitoxantrone were compared for their cardiotoxic potential in a chronic mouse model in… 
Highly Cited
1992
Highly Cited
1992
BACKGROUND Although doxorubicin is an anticancer agent with a wide spectrum of activity, therapy with this anthracycline must… 
1992
1992
ADR-529 protects against anthracycline cardiotoxicity, possibly by preventing free radical induction. We hypothesize that this…